Status:
RECRUITING
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate polypeptide sequences will be verified, manufactured and protected for vaccine production by multiple in vitro ...
Detailed Description
1. Choose appropriate patients with advanced solid cancers, with written consent for this study; 2. Perform biopsy to get fresh sample for DNA/RNA-seqencings and bioinformatics analysis; 3. Produce ap...
Eligibility Criteria
Inclusion
- 1\. Patients with advanced cancer; 2. Life expectancy \>12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available high quality vaccine for human use; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
- \-
Exclusion
- Had accepted gene therapy before;
- Severe virus infection such as HBV, HCV, HIV, et al;
- Known HIV positivity;
- Active infectious disease related to bacteria, virus,fungi,et al;
- Other severe diseases that the investigators consider not appropriate;
- Pregnant or lactating women;
- Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
- Other conditions that the investigators consider not appropriate.
Key Trial Info
Start Date :
June 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2037
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06195293
Start Date
June 4 2024
End Date
December 30 2037
Last Update
June 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China, 510260